138 related articles for article (PubMed ID: 22891198)
1. Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers.
Hu H; Zhang H; Ge W; Liu X; Loera S; Chu P; Chen H; Peng J; Zhou L; Yu S; Yuan Y; Zhang S; Lai L; Yen Y; Zheng S
Clin Cancer Res; 2012 Oct; 18(19):5438-48. PubMed ID: 22891198
[TBL] [Abstract][Full Text] [Related]
2. SPARCL1 expression increases with preoperative radiation therapy and predicts better survival in rectal cancer patients.
Kotti A; Holmqvist A; Albertsson M; Sun XF
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1196-202. PubMed ID: 24661672
[TBL] [Abstract][Full Text] [Related]
3. Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer.
Li P; Qian J; Yu G; Chen Y; Liu K; Li J; Wang J
J Surg Oncol; 2012 Jan; 105(1):31-7. PubMed ID: 22161898
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro.
Kahlert C; Lahes S; Radhakrishnan P; Dutta S; Mogler C; Herpel E; Brand K; Steinert G; Schneider M; Mollenhauer M; Reissfelder C; Klupp F; Fritzmann J; Wunder C; Benner A; Kloor M; Huth C; Contin P; Ulrich A; Koch M; Weitz J
Clin Cancer Res; 2011 Dec; 17(24):7654-63. PubMed ID: 22042972
[TBL] [Abstract][Full Text] [Related]
5. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma.
Yu Y; Chen Y; Ma J; Yu X; Yu G; Li Z
Tumour Biol; 2016 Mar; 37(3):4159-67. PubMed ID: 26490986
[TBL] [Abstract][Full Text] [Related]
6. Secreted protein acidic and rich in cysteine-like 1 suppresses metastasis in gastric stromal tumors.
Shen C; Yin Y; Chen H; Wang R; Yin X; Cai Z; Zhang B; Chen Z; Zhou Z
BMC Gastroenterol; 2018 Jul; 18(1):105. PubMed ID: 29973149
[TBL] [Abstract][Full Text] [Related]
7. Androgen-Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression.
Hurley PJ; Hughes RM; Simons BW; Huang J; Miller RM; Shinder B; Haffner MC; Esopi D; Kimura Y; Jabbari J; Ross AE; Erho N; Vergara IA; Faraj SF; Davicioni E; Netto GJ; Yegnasubramanian S; An SS; Schaeffer EM
Cancer Res; 2015 Oct; 75(20):4322-34. PubMed ID: 26294211
[TBL] [Abstract][Full Text] [Related]
8. SPARCL1 Is a Novel Prognostic Biomarker and Correlates with Tumor Microenvironment in Colorectal Cancer.
Zhang HP; Wu J; Liu ZF; Gao JW; Li SY
Biomed Res Int; 2022; 2022():1398268. PubMed ID: 35111844
[TBL] [Abstract][Full Text] [Related]
9. A colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential.
Fritzmann J; Morkel M; Besser D; Budczies J; Kosel F; Brembeck FH; Stein U; Fichtner I; Schlag PM; Birchmeier W
Gastroenterology; 2009 Jul; 137(1):165-75. PubMed ID: 19328798
[TBL] [Abstract][Full Text] [Related]
10. SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis.
Hu H; Cai W; Zheng S; Ge W
Cell Physiol Biochem; 2017; 44(4):1485-1496. PubMed ID: 29190626
[TBL] [Abstract][Full Text] [Related]
11. SPARCL1 suppresses metastasis in prostate cancer.
Xiang Y; Qiu Q; Jiang M; Jin R; Lehmann BD; Strand DW; Jovanovic B; DeGraff DJ; Zheng Y; Yousif DA; Simmons CQ; Case TC; Yi J; Cates JM; Virostko J; He X; Jin X; Hayward SW; Matusik RJ; George AL; Yi Y
Mol Oncol; 2013 Dec; 7(6):1019-30. PubMed ID: 23916135
[TBL] [Abstract][Full Text] [Related]
12. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome.
Hurley PJ; Marchionni L; Simons BW; Ross AE; Peskoe SB; Miller RM; Erho N; Vergara IA; Ghadessi M; Huang Z; Gurel B; Park BH; Davicioni E; Jenkins RB; Platz EA; Berman DM; Schaeffer EM
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):14977-82. PubMed ID: 22927397
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological significance of reduced SPARCL1 expression in human breast cancer.
Cao F; Wang K; Zhu R; Hu YW; Fang WZ; Ding HZ
Asian Pac J Cancer Prev; 2013; 14(1):195-200. PubMed ID: 23534723
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver.
Gray MJ; Van Buren G; Dallas NA; Xia L; Wang X; Yang AD; Somcio RJ; Lin YG; Lim S; Fan F; Mangala LS; Arumugam T; Logsdon CD; Lopez-Berestein G; Sood AK; Ellis LM
J Natl Cancer Inst; 2008 Jan; 100(2):109-20. PubMed ID: 18182619
[TBL] [Abstract][Full Text] [Related]
15. SPARCL1 suppresses cell migration and invasion in renal cell carcinoma.
Ye H; Wang WG; Cao J; Hu XC
Mol Med Rep; 2017 Nov; 16(5):7784-7790. PubMed ID: 28944877
[TBL] [Abstract][Full Text] [Related]
16. SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex.
Zhao SJ; Jiang YQ; Xu NW; Li Q; Zhang Q; Wang SY; Li J; Wang YH; Zhang YL; Jiang SH; Wang YJ; Huang YJ; Zhang XX; Tian GA; Zhang CC; Lv YY; Dai M; Liu F; Zhang R; Zhou D; Zhang ZG
Oncogene; 2018 Feb; 37(8):1049-1061. PubMed ID: 29084211
[TBL] [Abstract][Full Text] [Related]
17. Endothelial cell-derived fibronectin extra domain A promotes colorectal cancer metastasis via inducing epithelial-mesenchymal transition.
Ou J; Peng Y; Deng J; Miao H; Zhou J; Zha L; Zhou R; Yu L; Shi H; Liang H
Carcinogenesis; 2014 Jul; 35(7):1661-70. PubMed ID: 24743511
[TBL] [Abstract][Full Text] [Related]
18. SPARCL1 impedes trophoblast migration and invasion by down-regulating ERK phosphorylation and AP-1 production and altering EMT-related molecule expression.
Liu X; Zhao J; Luan X; Li S; Zhai J; Liu J; Du Y
Placenta; 2020 Jan; 89():33-41. PubMed ID: 31675488
[TBL] [Abstract][Full Text] [Related]
19. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-enkephalin in the liver.
Kuniyasu H; Luo Y; Fujii K; Sasahira T; Moriwaka Y; Tatsumoto N; Sasaki T; Yamashita Y; Ohmori H
Gut; 2010 Mar; 59(3):348-56. PubMed ID: 19828468
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells.
Herynk MH; Stoeltzing O; Reinmuth N; Parikh NU; Abounader R; Laterra J; Radinsky R; Ellis LM; Gallick GE
Cancer Res; 2003 Jun; 63(11):2990-6. PubMed ID: 12782608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]